On this page

Nystatin and Triamcinolone Acetonide

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Nystatin and Triamcinolone Acetonide
Generic name
Nystatin and Triamcinolone Acetonide
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
15
Packages
35
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 100000 [USP'U]/g 261178 View
Triamcinolone Acetonide 1 mg/g 1014314 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
50

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
207741
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 31, 2017
Sponsor
DR REDDYS
Products on application
1
Submissions recorded
1
Products approved under application 207741.
Product Trade name Form Strength Ingredient Status TE Flags
207741-001 NYSTATIN AND TRIAMCINOLONE ACETONIDE OINTMENT NYSTATIN; TRIAMCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 207741.
Type No. Action Status Date Review
Original application 1 Approved January 31, 2017 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251022). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251022 HUMAN PRESCRIPTION DRUG · 20250829 HUMAN PRESCRIPTION DRUG · 20240618 HUMAN PRESCRIPTION DRUG · 20221008

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Ointment, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION A thin film of Nystatin and Triamcinolone Acetonide Ointment, USP is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). Nystatin and Triamcinolone Acetonide Ointment, USP should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies. Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur. The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Nystatin and Triamcinolone Acetonide Ointment USP for dermatologic use contains the antifungal agent nystatin, USP and the synthetic corticosteroid triamcinolone acetonide, USP. Nystatin, USP is a polyene antimycotic obtained from Streptomyces noursei . It is a yellow to light tan powder, having an odor suggestive of cereals. Is hygroscopic, and is affected by long exposure to light, heat, and air. It freely soluble in dimethylformamide and in dimethyl sulfoxide, slightly to sparingly soluble in methanol, in n-propyl alcohol, and in n-butyl alcohol, practically insoluble in water and in alcohol; insoluble in chloroform and in ether. Structural formula: C 47 H 75 NO 17 MW = 926.11 g/mol Triamcinolone acetonide, USP is designated chemically as Pregna-1, 4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)-9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone. The white to cream colored, crystalline powder, having not more than a slight odor, is practically insoluble in water, sparingly soluble in dehydrated alcohol, in chloroform and in methanol. Structural formula: C 24 H 31 FO 6 MW = 434.50 g/mol Each gram of Nystatin and Triamcinolone Acetonide Ointment provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide, USP in an ointment base of mineral oil and white petrolatum. nystatin-image triamcinolone-structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General ); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin and Triamcinolone Acetonide Ointment, USP is supplied in 15g (NDC 21922-031-04), 30g (NDC 21922-031-05) and 60g (NDC 21922-031-07) tubes. STORAGE Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Avoid freezing. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-844-369-4671 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Rx only Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA Rev 01 November 2022

Adverse event reports

Source: openFDA FAERS
31,697
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
62332-585-15 62332-585 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-585-15) / 15 g in 1 TUBE March 15, 2022
62332-585-30 62332-585 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-585-30) / 30 g in 1 TUBE March 15, 2022
62332-585-60 62332-585 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-585-60) / 60 g in 1 TUBE March 15, 2022
63629-2495-1 63629-2495 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2495-1) / 60 g in 1 TUBE September 28, 2019
63629-2496-1 63629-2496 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2496-1) / 30 g in 1 TUBE September 28, 2019
63629-2497-1 63629-2497 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2497-1) / 15 g in 1 TUBE September 28, 2019
71335-2847-1 71335-2847 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2847-1) / 15 g in 1 TUBE October 22, 2025
71335-2857-1 71335-2857 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2857-1) / 30 g in 1 TUBE October 22, 2025
72162-1275-2 72162-1275 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1275-2) / 15 g in 1 TUBE September 26, 2023
72162-1275-3 72162-1275 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1275-3) / 30 g in 1 TUBE September 26, 2023
72162-1275-6 72162-1275 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1275-6) / 60 g in 1 TUBE September 26, 2023
72162-1403-2 72162-1403 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1403-2) / 15 g in 1 TUBE June 18, 2024
72162-1403-3 72162-1403 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1403-3) / 30 g in 1 TUBE June 18, 2024
72162-1403-6 72162-1403 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1403-6) / 60 g in 1 TUBE June 18, 2024
21922-031-04 21922-031 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-031-04) / 15 g in 1 TUBE September 28, 2019
21922-031-05 21922-031 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-031-05) / 30 g in 1 TUBE September 28, 2019
21922-031-07 21922-031 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-031-07) / 60 g in 1 TUBE September 28, 2019
68462-799-17 68462-799 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-799-17) / 15 g in 1 TUBE June 23, 2016
68462-799-35 68462-799 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-799-35) / 30 g in 1 TUBE June 23, 2016
68462-799-65 68462-799 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-799-65) / 60 g in 1 TUBE June 23, 2016
33342-483-15 33342-483 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-483-15) / 15 g in 1 TUBE September 1, 2021
33342-483-30 33342-483 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-483-30) / 30 g in 1 TUBE September 1, 2021
33342-483-60 33342-483 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-483-60) / 60 g in 1 TUBE September 1, 2021
45802-244-14 45802-244 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-244-14) / 15 g in 1 TUBE October 18, 2017
45802-244-94 45802-244 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-244-94) / 30 g in 1 TUBE October 18, 2017
45802-244-96 45802-244 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-244-96) / 60 g in 1 TUBE October 18, 2017
51672-1272-1 51672-1272 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1272-1) / 15 g in 1 TUBE March 29, 1993
51672-1272-2 51672-1272 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1272-2) / 30 g in 1 TUBE March 29, 1993
51672-1272-3 51672-1272 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1272-3) / 60 g in 1 TUBE March 29, 1993
72578-088-01 72578-088 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-088-01) / 15 g in 1 TUBE June 24, 2020
72578-088-02 72578-088 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-088-02) / 60 g in 1 TUBE June 24, 2020
72578-088-04 72578-088 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-088-04) / 30 g in 1 TUBE June 24, 2020
70771-1447-1 70771-1447 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1447-1) / 15 g in 1 TUBE November 20, 2018
70771-1447-2 70771-1447 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1447-2) / 30 g in 1 TUBE November 20, 2018
70771-1447-3 70771-1447 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1447-3) / 60 g in 1 TUBE November 20, 2018
62332-585 62332-585 Alembic Pharmaceuticals Inc. — March 15, 2022
63629-2495 63629-2495 Bryant Ranch Prepack — September 28, 2019
63629-2496 63629-2496 Bryant Ranch Prepack — September 28, 2019
63629-2497 63629-2497 Bryant Ranch Prepack — September 28, 2019
71335-2847 71335-2847 Bryant Ranch Prepack — September 28, 2019
71335-2857 71335-2857 Bryant Ranch Prepack — September 28, 2019
72162-1275 72162-1275 Bryant Ranch Prepack — September 28, 2019
72162-1403 72162-1403 Bryant Ranch Prepack — October 18, 2017
21922-031 21922-031 Encube Ethicals, Inc. — September 28, 2019
68462-799 68462-799 Glenmark Pharmaceuticals Inc., USA — June 23, 2016
33342-483 33342-483 Macleods Pharmaceuticals Limited — September 1, 2021
45802-244 45802-244 Padagis Israel Pharmaceuticals Ltd — October 18, 2017
51672-1272 51672-1272 Sun Pharmaceutical Industries, Inc. — March 29, 1993
72578-088 72578-088 Viona Pharmaceuticals Inc — June 24, 2020
70771-1447 70771-1447 Zydus Lifesciences Limited — November 20, 2018

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.